Biontech Se Sponsored Adr (BNTX)
NASDAQ:BNTX
BNTX Stock Chart & Stats
$88.41
-$4.73(-3.73%)
At close: 4:00 PM EST
$88.41
-$4.73(-3.73%)
Day’s Range― - ―
52-Week Range$79.52 - $124.00
Previous CloseN/A
Volume316.50K
Average Volume (3M)1.33M
Market Cap
$22.22B
Enterprise Value$11.49B
Total Cash (Recent Filing)$14.83B
Total Debt (Recent Filing)$267.29M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
May 11, 2026EPS Estimate
-2.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding252,531,940
10 Day Avg. Volume2,854,428
30 Day Avg. Volume1,330,388
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.02
Price to Sales (P/S)7.10
P/FCF Ratio72.58
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue4.02
Enterprise Value/Gross Profit5.17
Enterprise Value/Ebitda-18.10
Forecast
1Y Price Target
$137.47Price Target Upside55.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-4.28
Revenue Forecast (FY)$2.28B
Bulls Say, Bears Say
Bulls Say
Balance Sheet And ValuationA substantial cash position relative to enterprise value and a still-meaningful vaccine business provide financial flexibility to fund late-stage oncology studies and pursue business development, supporting asymmetric upside if clinical progress accelerates.
Lead Asset Commercial PotentialA lead bispecific immune therapy being tested alone and in combinations has the potential to become a next-generation backbone treatment, with indication expansion that could drive meaningful commercial revenues if trials succeed.
Pipeline ReadoutsSeveral upcoming late-stage clinical readouts across oncology programs, including trials of a next-generation bispecific immune therapy and tumor-targeted agents, could materially boost confidence in the pipeline if results are favorable.
Bears Say
Clinical And Execution RiskA large and ambitious oncology portfolio, together with prior trial setbacks and risks around enrollment and patient representation, increases the chance of missed milestones, delayed approvals, or negative trial outcomes that could weigh on the stock.
Leadership UncertaintyDeparture of the founding CEO and CMO creates executive leadership uncertainty while multiple critical clinical programs remain in development, increasing investor concern about strategic direction and execution.
Revenue Outlook PressureDeclining vaccine sales and softer revenue guidance shift investor focus to pipeline outcomes and raise sensitivity to near-term top-line weakness.
BioNTech SE News
BNTX FAQ
What was Biontech Se Sponsored Adr’s price range in the past 12 months?
Biontech Se Sponsored Adr lowest stock price was $79.52 and its highest was $124.00 in the past 12 months.
What is Biontech Se Sponsored Adr’s market cap?
Biontech Se Sponsored Adr’s market cap is $22.22B.
When is Biontech Se Sponsored Adr’s upcoming earnings report date?
Biontech Se Sponsored Adr’s upcoming earnings report date is May 11, 2026 which is in 47 days.
How were Biontech Se Sponsored Adr’s earnings last quarter?
Biontech Se Sponsored Adr released its earnings results on Mar 10, 2026. The company reported -$1.451 earnings per share for the quarter, missing the consensus estimate of -$0.188 by -$1.263.
Is Biontech Se Sponsored Adr overvalued?
According to Wall Street analysts Biontech Se Sponsored Adr’s price is currently Undervalued.
Does Biontech Se Sponsored Adr pay dividends?
Biontech Se Sponsored Adr pays a Notavailable dividend of $2.111 which represents an annual dividend yield of N/A. See more information on Biontech Se Sponsored Adr dividends here
What is Biontech Se Sponsored Adr’s EPS estimate?
Biontech Se Sponsored Adr’s EPS estimate is -2.56.
How many shares outstanding does Biontech Se Sponsored Adr have?
Biontech Se Sponsored Adr has 252,531,940 shares outstanding.
What happened to Biontech Se Sponsored Adr’s price movement after its last earnings report?
Biontech Se Sponsored Adr reported an EPS of -$1.451 in its last earnings report, missing expectations of -$0.188. Following the earnings report the stock price went down -17.884%.
Which hedge fund is a major shareholder of Biontech Se Sponsored Adr?
Currently, no hedge funds are holding shares in BNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioNTech SE Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$137.47 (55.49% Upside)
$137.47 (55.49% Upside)
Blogger Sentiment
Bullish
BNTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 300.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $106.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.74%
12-Months-Change
Fundamentals
Return on Equity
-6.03%
Trailing 12-Months
Asset Growth
10.69%
Trailing 12-Months
Company Description
Biontech Se Sponsored Adr
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
BNTX Company Deck
BNTX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
BioNTech showed strong progress in its oncology programs and financial position, highlighted by increased revenue and strategic advancements. However, challenges include significant financial losses and delays in product submissions due to regulatory discussions.View all BNTX earnings summariesBNTX Stock 12 Month Forecast
Average Price Target
$137.47
▲(55.49% Upside)
Technical Analysis
Ownership Overview
0.35% Insiders
6.47% Mutual Funds
10.21% Other Institutional Investors
81.89% Public Companies and Individual Investors